SOX2 and cancer: SOX2 expression has been linked to staging, relapse, therapy resistance, and overall prognosis in several human cancers, including lung, ovarian, urothelial, breast, pancreatic, colorectal, oesophageal, nasopharyngeal and even oral squamous cell carcinoma [12, 17, 18, 20–26].